Frost & Sullivan Awards Wedge's Pharmaceutical the "Global Intestinal Product Leadership Award" and "Global Gynecological Microecology Therapy Technology Innovation Leadership Award"

New York, New York--(Newsfile Corp. - December 13, 2025) - Based on research and analysis of the global microecology market, as well as the evaluation of relevant companies in the industry over recent years, Frost & Sullivan is proud to award Wedge's Pharmaceutical's Microecological Probiotics Sector (hereinafter referred to as "Wedge Pharma") the "Global Intestinal Product Leadership Award" and the "Global Gynecological Microecology Therapy Technology Innovation Leadership Award."

Wedge Pharma: Pioneering China's Microecology Therapeutic Solutions, Empowering a Healthier Global Future

Wedge Pharma, a core segment of the publicly listed Wedge (Stock Code: 000534) on the Shenzhen Stock Exchange, is a leading enterprise in the microecology therapeutics and female health sectors in China. With a long-standing focus on the research and commercialization of digestive and gynecological microecology, Wedge Pharma is currently the exclusive microecology formulation company in China with national high-tech qualifications in both therapeutic fields. Its two strategic products, the national class I new drug "Golden Bifid" and the exclusive gynecological microecology formulation "Ding Jun Sheng", have collectively served over 100 million patients.

For thirty years, Wedge Pharma has been deeply engaged in the microecology field, establishing a comprehensive industry system that includes R&D, production, multi-channel marketing, evidence-based research, and expert resources, forming a solid core competitiveness.

The core product, "Golden Bifid" is among the first approved microecology formulations in China and has become a leading brand in gastrointestinal microecology therapy. It is widely utilized in pediatrics, gastroenterology, geriatrics, and ICUs, earning trust for its significant efficacy, high safety profile, and good compliance. Another strategic product, "Ding Jun Sheng" is the globally exclusive, live vaginal microecology products, pioneering new pathways in gynecological microecology therapy. It has become an indispensable component in the comprehensive management of vaginal infections, through restoring microbial balance, enhancing biological resistance, and effectively addresses the limitations of traditional antibiotic treatments.